3/18
08:08 am
mltx
MoonLake Immunotherapeutics (NASDAQ: MLTX) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating and a $67.00 price target on the stock.
Low
Report
MoonLake Immunotherapeutics (NASDAQ: MLTX) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating and a $67.00 price target on the stock.
2/27
12:15 pm
mltx
MoonLake Immunotherapeutics (NASDAQ: MLTX) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $82.00 to $73.00. They now have a "buy" rating on the stock.
Low
Report
MoonLake Immunotherapeutics (NASDAQ: MLTX) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $82.00 to $73.00. They now have a "buy" rating on the stock.
2/27
08:08 am
mltx
MoonLake Immunotherapeutics (NASDAQ: MLTX) had its price target raised by analysts at Needham & Company LLC from $62.00 to $66.00. They now have a "buy" rating on the stock.
Low
Report
MoonLake Immunotherapeutics (NASDAQ: MLTX) had its price target raised by analysts at Needham & Company LLC from $62.00 to $66.00. They now have a "buy" rating on the stock.
2/27
08:08 am
mltx
MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.
Low
Report
MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.
2/26
10:55 am
mltx
MoonLake Immunotherapeutics reports Q4 results [Seeking Alpha]
Low
Report
MoonLake Immunotherapeutics reports Q4 results [Seeking Alpha]
2/26
07:00 am
mltx
MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update
Medium
Report
MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update
2/20
12:26 pm
mltx
MoonLake Immunotherapeutics (MLTX): Among the Most Oversold Healthcare Stocks to Buy Now [Yahoo! Finance]
Low
Report
MoonLake Immunotherapeutics (MLTX): Among the Most Oversold Healthcare Stocks to Buy Now [Yahoo! Finance]
2/11
06:34 am
mltx
We're Hopeful That MoonLake Immunotherapeutics (NASDAQ:MLTX) Will Use Its Cash Wisely [Yahoo! Finance]
Medium
Report
We're Hopeful That MoonLake Immunotherapeutics (NASDAQ:MLTX) Will Use Its Cash Wisely [Yahoo! Finance]
1/17
04:38 am
mltx
MoonLake Immunotherapeutics (NASDAQ: MLTX) was upgraded by analysts at The Goldman Sachs Group, Inc. from a "neutral" rating to a "buy" rating. They now have a $82.00 price target on the stock, up previously from $62.00.
Low
Report
MoonLake Immunotherapeutics (NASDAQ: MLTX) was upgraded by analysts at The Goldman Sachs Group, Inc. from a "neutral" rating to a "buy" rating. They now have a $82.00 price target on the stock, up previously from $62.00.
1/15
04:04 pm
mltx
MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab [Yahoo! Finance]
Medium
Report
MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab [Yahoo! Finance]
1/10
08:03 am
mltx
MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.
Medium
Report
MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.
1/8
07:00 am
mltx
MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab
Medium
Report
MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab